Alx Oncology Holdings Inc is a biotechnology company focused on developing innovative therapies for patients suffering from cancer
The company specializes in creating novel immuno-oncology treatments that harness the power of the immune system to target and eliminate cancer cells. Through its proprietary platform, Alx Oncology aims to address significant unmet medical needs in oncology by advancing its drug candidates through clinical trials, striving to improve outcomes for patients with various types of malignancies. The company's research is driven by a commitment to scientific excellence and the goal of transforming cancer care.
ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel for HER2-positive gastric/GEJ cancer. The trial shows significant improvements in overall response rate and duration of response.
ALX Oncology's evorpacept, poised for pivotal HER2+ gastric cancer development. Caution prevails due to sub-$100 million market size; await additional plans backed by phase 1/2 data.
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQKRTX) rose sharply during Friday’s session following acquisition news.
ALX Oncology Holdings Inc (NASDAQALXO) shares are trading higher by 5.9% to $6.76 Thursday morning. The company announced the pricing of a public offering consisting of roughly 7.37 million common stock shares at $6.38 per share and 1.25 million pre-
